Johnson & Johnson’s new psoriasis pill, Icotyde, is a big win for systemic treatment options—but it does not replace the need for safe, convenient home UVB for many people living with psoriasis, especially those who want a non-drug or combination approach.
What Icotyde Is and Why It Matters
Icotyde (icotrokinra) is the first FDA‑approved targeted oral IL‑23 receptor antagonist for moderate‑to‑severe plaque psoriasis in adults and adolescents 12+ who are candidates for systemic therapy or phototherapy. It is a once‑daily peptide pill designed to block the IL‑23 receptor, a key driver of psoriasis inflammation, and aims to offer “biologic‑like” skin clearance without injections.
In Phase 3 trials, roughly 70–74% of patients achieved clear or almost clear skin, with a favorable safety profile in studies including about 2,500 participants. J&J expects Icotyde to compete directly with injectable IL‑23 drugs like Tremfya and Skyrizi, particularly for patients who avoid injections or never move beyond topicals.
What This Means to You
For Cytokind members, Icotyde expands the menu of systemic options that can be paired with, or considered alongside, home NB‑UVB phototherapy prescribed by your medical provider. Many guidelines already view both systemic drugs and phototherapy as appropriate next steps after topicals for moderate‑to‑severe psoriasis, and Icotyde simply adds a new oral choice into that systemic tier.[10][3][6][4][5][2]
NB‑UVB remains a foundational non‑drug therapy that can match the clinical performance of some biologics and often delivers excellent quality‑of‑life outcomes, especially when patients can be treated at home instead of traveling to a clinic multiple times per week. Cytokind’s role is to help you and your prescribing clinician integrate home phototherapy into your overall plan—whether that plan includes only light, light plus topicals, or light plus systemic medications.
Systemic Pill vs NB‑UVB at a Glance
| Aspect | Icotyde pill | NB‑UVB (Cytokind home) |
| Route | Once‑daily oral drug. | Non‑drug light treatment at home. |
| Target | IL‑23 receptor, systemic immune modulation. | Targets skin immune cells, modulates inflammation locally and systemically. |
| Typical use | Moderate‑to‑severe plaque psoriasis candidates for systemic therapy or phototherapy. | Patients who failed topicals or need a non‑drug / adjunct option. |
| Injections | None; oral alternative to IL‑23 shots. | None; device‑based therapy. |
| Place in care | New first‑line systemic option. | Established option that can be first‑line phototherapy and an adjunct to drugs. |
Can You Combine a Drug Like Icotyde With UVB?
Combination therapy (a systemic drug plus NB‑UVB) is already common in psoriasis care; multiple studies have shown that NB‑UVB can be used safely alongside systemic agents like methotrexate to improve clearance and speed response. Dermatologists often use light therapy in combination with systemic therapy to reduce total drug exposure, achieve faster improvement, or target stubborn areas such as the scalp, hands, or feet.
However, every drug has its own safety profile, and Icotyde is new, so the decision to combine it with NB‑UVB must be individualized and made by your prescribing dermatologist, based on your skin type, history, and other medications. Cytokind does not prescribe or manage medications—but we work with your medical provider to ensure your home NB‑UVB protocol aligns with your overall treatment plan.
How Cytokind Fits Into the New Landscape
Even as advanced drugs like Icotyde come to market, many people still want or need:
- A non‑drug treatment option they can control at home.
- A way to complement systemic therapy for more complete or faster clearance.
- A long‑term maintenance strategy that may help minimize reliance on higher‑dose systemic medications, as appropriate for their case.
Cytokind helps you access medical-provider-supervised, at‑home NB‑UVB therapy with education, safety protocols, and support, so light therapy can sit confidently alongside the rest of your care. To see how home UVB could fit with your current or future psoriasis treatment—whether that includes a drug like Icotyde or not—schedule a 10‑minute discovery call with us.
This blog post is for informational purposes only and does not constitute medical advice. Individuals should consult with qualified healthcare providers before beginning any new treatment modality.
